IDH1 and cholangiocarcinoma: The recent FDA approvals of FGFR inhibitors pemigatinib, infigratinib and futibatinib,31 as well as the mutant IDH1 inhibitor ivosidenib,32 for the treatment of advanced CCA patients underscore the potential of targeted therapies in addressing this aggressive disease.